Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA™ by the U.S. FDA

KING OF PRUSSIA, Pa., July 20, 2017 /PRNewswire/ -- Churchill Pharmaceuticals, LLC (Churchill), a privately held company devoted to expanding treatment options...

July 20, 2017


Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate

Click here to view the article.

July 10, 2017


Churchill Pharmaceuticals Expands Commercial Leadership Team

King of Prussia, PA., May 30, 2017 Churchill Pharmaceuticals, LLC (Churchill), a clinical-stage biopharmaceutical company, today announced the expansion of...

May 30, 2017


Churchill Pharmaceuticals Announces Submission of NDA for Novel Oral Formulation of Prostate Cancer Treatment

King of Prussia, PA., May 23, 2017 Churchill Pharmaceuticals, LLC (Churchill) today announced it has submitted a New Drug Application...

May 23, 2017


Churchill Pharmaceuticals launches a new updated website with a fresh design

King of Prussia, PA., May 16, 2017 Churchill Pharmaceuticals, a drug development biopharmaceutical company specialized in oral oncology, announced the...

May 22, 2017


Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects, Clinical Pharmacokinetics 2017

Click here to view the article.

May 5, 2017